Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer, Familial Male|Radiotherapy; Complications|Chemotherapeutic Toxicity|Immune Checkpoint Inhibitor|CDK4/6 Inhibitor|Trastuzumab|Pertuzumab|PARP Inhibitor
Interventions: RADIATION: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences